WO2008111441A1 - 医薬組成物 - Google Patents

医薬組成物 Download PDF

Info

Publication number
WO2008111441A1
WO2008111441A1 PCT/JP2008/053909 JP2008053909W WO2008111441A1 WO 2008111441 A1 WO2008111441 A1 WO 2008111441A1 JP 2008053909 W JP2008053909 W JP 2008053909W WO 2008111441 A1 WO2008111441 A1 WO 2008111441A1
Authority
WO
WIPO (PCT)
Prior art keywords
flt
inhibitor
hydrogen atom
pharmaceutical composition
substituted
Prior art date
Application number
PCT/JP2008/053909
Other languages
English (en)
French (fr)
Inventor
Yukimasa Shiotsu
Kenichi Ishii
Hiroyuki Ishida
Makiko Shimizu
Original Assignee
Kyowa Hakko Kirin Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co., Ltd. filed Critical Kyowa Hakko Kirin Co., Ltd.
Priority to JP2009503983A priority Critical patent/JPWO2008111441A1/ja
Priority to EP08721329A priority patent/EP2133095A4/en
Priority to US12/529,425 priority patent/US20100104567A1/en
Priority to CA002680122A priority patent/CA2680122A1/en
Publication of WO2008111441A1 publication Critical patent/WO2008111441A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

　Flt-3阻害剤と、少なくとも1つの化合物とを組み合わせてなる医薬組成物、 Flt-3阻害剤が式（I）（式中、R1は置換もしくは非置換のアリール等を表す）で表されるインダゾール誘導体またはその薬理学的に許容される塩である前記医薬組成物、 Flt-3阻害剤が式（II）［式中、-X-Y-Z-は-O-CR17=N-（式中、R17は水素原子、低級アルキル等を表す）を表し、R15は-NR22aR22b（式中、R22a及びR22bは同一または異なって、水素原子、置換もしくは非置換の低級アルキル等を表す）を表し、R16は-NR24aR24b（式中、R24a及びR24bは同一または異なって、水素原子、低級アルキル等を表す）等を表す］で表されるピリミジン誘導体またはその薬理学的に許容される塩である前記医薬組成物等を提供する。
PCT/JP2008/053909 2007-03-05 2008-03-05 医薬組成物 WO2008111441A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2009503983A JPWO2008111441A1 (ja) 2007-03-05 2008-03-05 医薬組成物
EP08721329A EP2133095A4 (en) 2007-03-05 2008-03-05 PHARMACEUTICAL COMPOSITION
US12/529,425 US20100104567A1 (en) 2007-03-05 2008-03-05 Pharmaceutical composition
CA002680122A CA2680122A1 (en) 2007-03-05 2008-03-05 Pharmaceutical composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007053676 2007-03-05
JP2007-053676 2007-03-05

Publications (1)

Publication Number Publication Date
WO2008111441A1 true WO2008111441A1 (ja) 2008-09-18

Family

ID=39759384

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/053909 WO2008111441A1 (ja) 2007-03-05 2008-03-05 医薬組成物

Country Status (8)

Country Link
US (1) US20100104567A1 (ja)
EP (1) EP2133095A4 (ja)
JP (1) JPWO2008111441A1 (ja)
KR (1) KR20090115866A (ja)
CN (1) CN101622015A (ja)
CA (1) CA2680122A1 (ja)
TW (1) TW200901975A (ja)
WO (1) WO2008111441A1 (ja)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012115226A1 (ja) * 2011-02-24 2012-08-30 協和発酵キリン株式会社 癌治療剤
US10716790B2 (en) 2015-02-20 2020-07-21 Daiichi Sankyo Company, Limited Method for treating cancer by combined use
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP2022024031A (ja) * 2015-11-11 2022-02-08 セレーター ファーマシューティカルズ インコーポレイテッド 白血病に罹患している対象の治療レジメンを選択するためのアッセイ及び方法

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100589032B1 (ko) 2000-10-20 2006-06-14 에자이 가부시키가이샤 질소 함유 방향환 유도체
AU2005283422C1 (en) 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
AU2006309551B2 (en) 2005-11-07 2012-04-19 Eisai R & D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
CN101443009A (zh) 2006-05-18 2009-05-27 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
WO2008026748A1 (fr) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Agent antitumoral pour cancer gastrique non différencié
US8962655B2 (en) 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
TW200901960A (en) * 2007-03-05 2009-01-16 Kyowa Hakko Kogyo Kk Pharmaceutical composition
JP5638244B2 (ja) 2007-11-09 2014-12-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質と抗腫瘍性白金錯体との併用
US9290499B2 (en) 2010-05-19 2016-03-22 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US20120045433A1 (en) * 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
EP2700403B1 (en) 2011-04-18 2015-11-25 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
US9567326B2 (en) * 2012-05-22 2017-02-14 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
US9562047B2 (en) 2012-10-17 2017-02-07 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
CN103804381A (zh) * 2012-11-06 2014-05-21 韩冰 一类治疗缺血性脑损伤的化合物及其用途
CN103800340A (zh) * 2012-11-09 2014-05-21 韩冰 一类治疗青光眼的化合物及其用途
EP2925752A4 (en) 2012-11-27 2016-06-01 Univ North Carolina PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
SG11201509278XA (en) 2013-05-14 2015-12-30 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
US20150291609A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrimidine compounds
PL3524595T3 (pl) 2014-08-28 2022-10-31 Eisai R&D Management Co., Ltd. Pochodna chinoliny o wysokiej czystości i sposób jej wytwarzania
SI3263106T1 (sl) 2015-02-25 2024-02-29 Eisai R&D Management Co., Ltd. Postopek zatiranja grenkobe derivata kinolina
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
MX2017015896A (es) 2015-06-16 2018-08-09 Eisai R&D Man Co Ltd Agente anticancerigeno.
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
KR20210002015A (ko) * 2019-06-27 2021-01-06 한미약품 주식회사 Flt3 저해제 및 화학치료제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물

Citations (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2141063A1 (de) 1971-08-17 1973-03-01 Agfa Gevaert Ag Verbessertes photographisches material
JPH0232059A (ja) 1988-07-18 1990-02-01 Kyowa Hakko Kogyo Co Ltd インダゾール誘導体
WO1992001675A2 (en) 1990-07-24 1992-02-06 Rhone-Poulenc Rorer S.A. Substituted bicyclic bis-aryl compounds exhibiting selective leukotriene b4 antagonist activity, their preparation and use in pharmaceutical compositions
WO1994014780A1 (en) 1992-12-18 1994-07-07 The Wellcome Foundation Limited Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
JPH1087492A (ja) 1996-06-25 1998-04-07 Ono Pharmaceut Co Ltd 一酸化窒素産生阻害剤
WO1999019305A2 (en) 1997-10-15 1999-04-22 Krenitsky Pharmaceuticals Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
WO1999032117A1 (en) 1997-12-22 1999-07-01 Sibia Neurosciences, Inc. Novel substituted pyridine compounds useful as modulators of acetylcholine receptors
US5935966A (en) 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
WO1999041253A1 (en) 1998-02-17 1999-08-19 Tularik Inc. Anti-viral pyrimidine derivatives
WO2000039101A1 (en) 1998-12-24 2000-07-06 Astrazeneca Ab Pyrimidine compounds
WO2001000213A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
WO2001002369A2 (en) 1999-07-02 2001-01-11 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
WO2001017995A1 (en) 1999-09-10 2001-03-15 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2001053268A2 (en) 2000-01-18 2001-07-26 Agouron Pharmaceuticals, Inc. Indazole compounds, pharmaceutical compositions, and their use for mediating or inhibiting cell proliferation
WO2002010137A2 (en) 2000-07-31 2002-02-07 Signal Pharmaceuticals, Inc. Indazole derivatives as jnk inhibitors
WO2002020495A2 (en) 2000-09-06 2002-03-14 Chiron Corporation Inhibitors of glycogen synthase kinase 3
WO2002022608A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002030358A2 (en) 2000-10-11 2002-04-18 Tularik Inc. Modulation of ccr4 function
WO2002062789A1 (en) 2000-12-21 2002-08-15 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002083648A1 (en) 2001-04-16 2002-10-24 Eisai Co., Ltd. Novel 1h-indazole compound
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2003101968A1 (fr) 2002-05-31 2003-12-11 Eisai Co., Ltd. Compose de pyrazole et composition medicinale le contenant
WO2004050088A1 (ja) 2002-12-03 2004-06-17 Kyowa Hakko Kogyo Co., Ltd. Ｊｎｋ阻害剤
WO2004094388A2 (en) 2003-04-16 2004-11-04 Signal Pharmaceuticals, Llc Indazole derivatives as jnk inhibitors
WO2004108672A1 (en) 2003-06-02 2004-12-16 Abbott Laboratories Isoindolin-1-one compounds as kinase inhibitors
WO2005000778A1 (ja) 2003-06-27 2005-01-06 Kyowa Hakko Kogyo Co., Ltd. Hsp90ファミリー蛋白質阻害剤
WO2005012258A1 (ja) 2003-07-30 2005-02-10 Kyowa Hakko Kogyo Co., Ltd. タンパク質キナーゼ阻害剤
WO2005012257A1 (ja) 2003-07-30 2005-02-10 Kyowa Hakko Kogyo Co., Ltd. インダゾール誘導体
WO2005039564A1 (en) 2003-10-02 2005-05-06 Vertex Pharmaceuticals Incorporated Phthalimide compounds useful as protein kinase inhibitors
US20050137171A1 (en) 2003-12-17 2005-06-23 Aventis Pharma S.A. Novel organophosphorus derivatives of indazoles and use thereof as medicinal products
WO2005095382A1 (ja) 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. 抗腫瘍剤
WO2005094823A1 (ja) 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. Ｆｌｔ－３阻害剤
WO2005095341A1 (ja) 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. 含窒素複素環化合物
WO2006120557A1 (en) 2005-05-12 2006-11-16 Pfizer Inc. Anticancer combination therapy using sunitinib malate
WO2006135629A1 (en) * 2005-06-10 2006-12-21 Janssen Pharmaceutica N.V. Synergistic modulation of flt3 kinase using alkylquinolines and alkylquinazolines
WO2007010013A2 (en) * 2005-07-20 2007-01-25 Novartis Ag Combination comprising a pyrimidylaminobenzamides and a flt-3 inhibitor for treating proliferative diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor

Patent Citations (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2141063A1 (de) 1971-08-17 1973-03-01 Agfa Gevaert Ag Verbessertes photographisches material
JPH0232059A (ja) 1988-07-18 1990-02-01 Kyowa Hakko Kogyo Co Ltd インダゾール誘導体
WO1992001675A2 (en) 1990-07-24 1992-02-06 Rhone-Poulenc Rorer S.A. Substituted bicyclic bis-aryl compounds exhibiting selective leukotriene b4 antagonist activity, their preparation and use in pharmaceutical compositions
WO1994014780A1 (en) 1992-12-18 1994-07-07 The Wellcome Foundation Limited Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
US5935966A (en) 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
JPH1087492A (ja) 1996-06-25 1998-04-07 Ono Pharmaceut Co Ltd 一酸化窒素産生阻害剤
WO1999019305A2 (en) 1997-10-15 1999-04-22 Krenitsky Pharmaceuticals Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
WO1999032117A1 (en) 1997-12-22 1999-07-01 Sibia Neurosciences, Inc. Novel substituted pyridine compounds useful as modulators of acetylcholine receptors
WO1999041253A1 (en) 1998-02-17 1999-08-19 Tularik Inc. Anti-viral pyrimidine derivatives
WO2000039101A1 (en) 1998-12-24 2000-07-06 Astrazeneca Ab Pyrimidine compounds
WO2001000213A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
JP2003523942A (ja) 1999-06-30 2003-08-12 メルク エンド カムパニー インコーポレーテッド Ｓｒｃキナーゼ阻害剤化合物
WO2001002369A2 (en) 1999-07-02 2001-01-11 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
WO2001017995A1 (en) 1999-09-10 2001-03-15 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2001053268A2 (en) 2000-01-18 2001-07-26 Agouron Pharmaceuticals, Inc. Indazole compounds, pharmaceutical compositions, and their use for mediating or inhibiting cell proliferation
WO2002010137A2 (en) 2000-07-31 2002-02-07 Signal Pharmaceuticals, Inc. Indazole derivatives as jnk inhibitors
WO2002020495A2 (en) 2000-09-06 2002-03-14 Chiron Corporation Inhibitors of glycogen synthase kinase 3
WO2002022602A2 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Triazole compounds useful as protein kinase inhibitors
WO2002022601A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002022608A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002030358A2 (en) 2000-10-11 2002-04-18 Tularik Inc. Modulation of ccr4 function
WO2002062789A1 (en) 2000-12-21 2002-08-15 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002083648A1 (en) 2001-04-16 2002-10-24 Eisai Co., Ltd. Novel 1h-indazole compound
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2003101968A1 (fr) 2002-05-31 2003-12-11 Eisai Co., Ltd. Compose de pyrazole et composition medicinale le contenant
WO2004050088A1 (ja) 2002-12-03 2004-06-17 Kyowa Hakko Kogyo Co., Ltd. Ｊｎｋ阻害剤
WO2004094388A2 (en) 2003-04-16 2004-11-04 Signal Pharmaceuticals, Llc Indazole derivatives as jnk inhibitors
WO2004108672A1 (en) 2003-06-02 2004-12-16 Abbott Laboratories Isoindolin-1-one compounds as kinase inhibitors
WO2005000778A1 (ja) 2003-06-27 2005-01-06 Kyowa Hakko Kogyo Co., Ltd. Hsp90ファミリー蛋白質阻害剤
WO2005012258A1 (ja) 2003-07-30 2005-02-10 Kyowa Hakko Kogyo Co., Ltd. タンパク質キナーゼ阻害剤
WO2005012257A1 (ja) 2003-07-30 2005-02-10 Kyowa Hakko Kogyo Co., Ltd. インダゾール誘導体
WO2005039564A1 (en) 2003-10-02 2005-05-06 Vertex Pharmaceuticals Incorporated Phthalimide compounds useful as protein kinase inhibitors
US20050137171A1 (en) 2003-12-17 2005-06-23 Aventis Pharma S.A. Novel organophosphorus derivatives of indazoles and use thereof as medicinal products
WO2005095382A1 (ja) 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. 抗腫瘍剤
WO2005094823A1 (ja) 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. Ｆｌｔ－３阻害剤
WO2005095341A1 (ja) 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. 含窒素複素環化合物
WO2006120557A1 (en) 2005-05-12 2006-11-16 Pfizer Inc. Anticancer combination therapy using sunitinib malate
WO2006135629A1 (en) * 2005-06-10 2006-12-21 Janssen Pharmaceutica N.V. Synergistic modulation of flt3 kinase using alkylquinolines and alkylquinazolines
WO2007010013A2 (en) * 2005-07-20 2007-01-25 Novartis Ag Combination comprising a pyrimidylaminobenzamides and a flt-3 inhibitor for treating proliferative diseases

Non-Patent Citations (28)

* Cited by examiner, † Cited by third party
Title
"Clinical oncology", JAPANESE JOURNAL OF CANCER AND CHEMOTHERAPY PUBLISHERS INC
ABRAMS T.J. ET AL.: "Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer", MOL. CANCER THER., vol. 2, no. 10, 2003, pages 1011 - 1121, XP009070150 *
ADVANCES IN DRUG RES., vol. 13, 1984, pages 224 - 331
ALESKOG A. ET AL.: "In vitro activity of the flt3-inhibitor su5614 and standard cytotoxic agents in tumour cells from patients wth wild type and mutated flt3 acute method leukaemia", LEUK. RES., vol. 29, no. 9, 2005, pages 1079 - 1081, XP004984414 *
BAGRINTSEVA K. ET AL.: "FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L)", BLOOD, vol. 105, no. 9, 2005, pages 3679 - 3685, XP003015407 *
BALI P. ET AL.: "Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3", CLIN. CANCER RES., vol. 10, no. 15, 2004, pages 4991 - 4997, XP002472723 *
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 14, 2004, pages 4505
BLOOD, vol. 104, 2004, pages 1145
BLOOD, vol. 104, 2004, pages 4202
BLOOD, vol. 96, 2000, pages 3907
BLOOD, vol. 97, 2001, pages 2434
BUNDGAARD: "Design of Prodrugs", 1985, ELSEVIER PRESS AND THE LIKE
CELL, vol. 65, 1991, pages 1143
CLINICAL CANCER RESEARCH, vol. 10, 2004, pages 4991
DRUG DEV. RES., vol. 34, 1995, pages 220 - 230
GEORGE P. ET AL.: "Cotreatment with 17-allylamino-demethoxygeldanamycin and FTL-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3", CANCER RES., vol. 64, no. 10, 2004, pages 3645 - 3652, XP008091320 *
HETEROCYCLES, vol. 45, 1997, pages 2217
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY, BIOLOGY, PHYSICS, vol. 5, 1979, pages 85 - 91
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY, BIOLOGY, PHYSICS, vol. 85, no. 1979, 1979, pages 1145
J. MED. CHEM., vol. 40, 1997, pages 2011 - 2016
KHIMIYA, GETEROTSIKLICHESKIKH SOEDINENII, vol. 7, 1978, pages 957
LEUKEMIA, vol. 11, 1997, pages 1447
LEVIS M. ET AL.: "In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects", BLOOD, vol. 104, no. 4, 2004, pages 1145 - 1150, XP008117633 *
MOHI M.G. ET AL.: "Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs", PROC. NATL. ACAD. SCI. U.S.A., vol. 101, no. 9, 2004, pages 3130 - 3135, XP002424387 *
PROCEEDING OF NATIONAL ACADEMY OF SCIENCE OF THE UNITED STATES OF AMERICA, vol. 101, 2004, pages 3130
ROSS J.S. ET AL.: "Targeted therapies for cancer 2004", AM. J. CLIN. PATHOL., vol. 122, no. 4, 2004, pages 598 - 609, XP009071882 *
See also references of EP2133095A4 *
YANAMANDRA N. ET AL.: "Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia", CLIN. CANCER RES., vol. 12, no. 2, 2006, pages 591 - 599, XP008117634 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012115226A1 (ja) * 2011-02-24 2012-08-30 協和発酵キリン株式会社 癌治療剤
US10716790B2 (en) 2015-02-20 2020-07-21 Daiichi Sankyo Company, Limited Method for treating cancer by combined use
JP2022024031A (ja) * 2015-11-11 2022-02-08 セレーター ファーマシューティカルズ インコーポレイテッド 白血病に罹患している対象の治療レジメンを選択するためのアッセイ及び方法
US11746386B2 (en) 2015-11-11 2023-09-05 Celator Pharmaceuticals, Inc. Assays and methods for selecting a treatment regimen for a subject with leukemia
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Also Published As

Publication number Publication date
KR20090115866A (ko) 2009-11-09
JPWO2008111441A1 (ja) 2010-06-24
EP2133095A4 (en) 2012-09-26
CA2680122A1 (en) 2008-09-18
EP2133095A1 (en) 2009-12-16
CN101622015A (zh) 2010-01-06
US20100104567A1 (en) 2010-04-29
TW200901975A (en) 2009-01-16

Similar Documents

Publication Publication Date Title
WO2008111441A1 (ja) 医薬組成物
WO2008108386A1 (ja) 医薬組成物
MX2010002098A (es) Compuesto policiclico.
EP1642880A4 (en) PROTEIN INHIBITOR OF THE HSP90 FAMILY
EA200870336A1 (ru) Полициклические производные циннамида
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
EP1798226A4 (en) TRAIZOL DERIVATIVE
CA2565660A1 (en) Ortho substituted aryl or heteroaryl amide compounds
EP1845081A4 (en) amide
WO2008114817A1 (ja) 新規なアデニン化合物
TN2009000024A1 (en) Prodrug of cinnamide compound
EP1813270A4 (en) PROTEIN INHIBITORS OF THE HSP90 FAMILY
WO2008087933A1 (ja) ＩκＢキナーゼβ阻害活性を有する新規インドール誘導体
MX2013002558A (es) Derivado de imidazol de heteroanillo fusionado que tiene efecto de activacion de proteina cinasa activada por monofosfato de adenosina (amk).
ATE532770T1 (de) Imidazolderivat
WO2005105732A8 (en) Substituted methyl aryl or heteroaryl amide compounds
WO2009069736A1 (ja) 含窒素化合物
WO2008114812A1 (ja) Jak阻害剤
RS51949B (en) INHIBITORI KINAZE
TW200726470A (en) 6,7-unsaturated-7-carbamoylmorphinan derivatives
WO2008126901A1 (ja) 含窒素複素環化合物およびそれを含有する医薬組成物
WO2008140099A1 (ja) テトラゾイルオキシム誘導体および植物病害防除剤
TW200637539A (en) CTGF inhibitors
WO2008153042A1 (ja) 抗腫瘍剤
MX2010001566A (es) Derivado de aminopirazolamida.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880007135.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08721329

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009503983

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2680122

Country of ref document: CA

Ref document number: 1020097018568

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008721329

Country of ref document: EP